GSK’s Jemperli approved in EU as treatment for endometrial cancer
December 11, 2023Medical Communications EU, GSK, Jemperli, Oncology, endometrial cancer
GSK has announced that the European Commission (EC) has granted marketing authorisation to Jemperli (dostarlimab) in combination with carboplatin-paclitaxel chemotherapy, …
Daiichi Sankyo shares results for Ezharmia as lymphoma treatment
December 11, 2023Medical Communications Daiichi Sankyo, Ezharmia, Oncology, lymphoma
Daiichi Sankyo has announced results from the phase 2 VALENTINE-PTCL01 trial of Ezharmia (valemetostat tosilate), which demonstrated a clinically meaningful …
Regeneron shares data for multiple myeloma treatment
December 8, 2023Medical Communications Cancer, Oncology, Regeneron, clinical trial
Regeneron Pharmaceuticals has announced positive data from the pivotal LINKER-MM1 trial which assessed linvoseltamab as a treatment for patients with …
Merck collaborates with Acceleration Consortium for AI experimentation
December 8, 2023Research and Development AI, Acceleration Consortium, Merck, Pharmacy, experimentation
Merck and the Acceleration Consortium have announced their AI-driven experimentation planner Bayesian Back End (BayBE) is now available open-source on …
AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn
December 7, 2023Business Services AbbVie, Cerevel Therapeutics, Neurology, acquisition
AbbVie and Cerevel Therapeutics have announced an agreement in which AbbVie will acquire Cerevel Therapeutics for $45 per share, or …
ONK Therapeutics and NAYA Biosciences enter partnership for NK cell therapy development
December 7, 2023Research and Development NAYA Biosciences, NK cell therapies, ONK Therapeutics, Oncology, partnership
ONK Therapeutics and NAYA Biosciences have announced that they have entered into a research partnership to assess combination therapies consisting …
FDA approves Novartis’ Fabhalta for PNH treatment
December 6, 2023Medical Communications FDA, Fabhalta, Haematology, Novartis, PNH
Novartis has announced that the US Food and Drug Administration has approved Fabhalta (iptacopan) as the first oral monotherapy for …
Teva Pharmaceuticals shares phase 3 data for Ajovy as migraine treatment
December 6, 2023Research and Development Neurology, Teva Pharmaceuticals, ajovy, obesity
Teva Pharmaceuticals has announced data from a post hoc analysis of two phase 3 clinical studies around the effectiveness of …
British Medical Journal publishes letter calling on government to reduce rate of antidepressant prescribing
December 5, 2023Medical Communications British Medical Journal, Neurology, antidepressants, over-prescribing
A group of medical professionals and politicians have published an open letter in the British Medical Journal which calls on …
Genentech shares positive results from phase 3 trial for breast cancer treatment
December 5, 2023Research and Development Genentech, Oncology, breast cancer, oncology
Genentech, a member of the Roche Group, has announced positive results from the phase 3 INAVO120 study, which assessed the …
Dr Stefano Gulià appointed as chief scientific officer of Kling Bio
December 5, 2023Business Services Kling Bio, Oncology, appointment, chief scientific officer
Kling Bio has announced the appointment of Dr Stefano Gulià as chief scientific officer. Dr Gulià has over 15 years …
Roche to acquire Carmot Therapeutics for $2.7bn
December 4, 2023Business Services Obesity, Roche, acquisition, diabetes
Roche has announced that it has entered into a definitive merger agreement with Carmot Therapeutics, in which it will acquire …
Eli Lilly’s Jaypirca approved in US for leukaemia and lymphoma treatment
December 4, 2023Medical Communications Eli Lilly, FDA, Jaypirca, Oncology, leukaemia, lymphoma
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Jaypirca (pirtobrutinib, 100mg and 50mg tablets) …
GSK shares data from global shingles survey
December 1, 2023Medical Communications GSK, Infections and infestations, data, shingles
GSK has announced data from its new global survey about shingles. The data suggests that there are some significant gaps …
AbbVie to acquire ImmunoGen for approximately $10.1bn
December 1, 2023Sales and Marketing AbbVie, Oncology, acquisition
AbbVie and ImmunoGen have announced that AbbVie will acquire ImmunoGen and its lead cancer therapy Elahere (mirvetuximab soratansine-gynx), a first …
FDA accepts NDA for Karuna’s schizophrenia treatment
November 30, 2023Medical Communications FDA, Karuna Therapeutics, NDA, Neurology, schizophrenia
Karuna Therapeutics has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for …
Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device
November 30, 2023Medical Communications Devices, FDA, Vivos Therapeutics, sleep apnea
Vivos Therapeutics has announced that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for the …
Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance
November 29, 2023Research and Development Oncology, Tolremo, clinical trial, drug resistance, solid tumours
Tolremo Therapeutics has announced that it has dosed the first patient in its first-in-human clinical trial to assess the safety, …
FDA grants breakthrough device designation to Inflammatix’s TriVerity Acute Infection and Sepsis Test System
November 29, 2023Research and Development FDA, Infections and infestations, Inflammatix, TriVerity, infection, sepsis
Inflammatix has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the company’s lead …
FDA accepts new drug application for Orexo’s opioid overdose medication
November 28, 2023Research and Development FDA, Opioid overdose, Pharmacy, opioids, orexo
Orexo has announced that its New Drug Application (NDA) for OX124 has been accepted for review by the US Food …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
